Disease Detail

ID DOID:50929
Name mucosal melanoma
Definition A melanoma that has_material_basis_in melanocytes located_in mucosal membranes lining the respiratory, gastrointestinal and urogenital tract.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer cell type cancer melanoma mucosal melanoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
KIT C443S Imatinib mucosal melanoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT02748564 Phase II Aldesleukin + Pembrolizumab Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma Recruiting
NCT02818023 Phase I Pembrolizumab + Vemurafenib Dose-seeking and Efficacy Study of Pembrolizumab Plus Vemurafenib Advanced Melanoma Recruiting
NCT02879162 Phase II Durvalumab + Tremelimumab Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours Recruiting
NCT02978443 Phase II Nivolumab + Ipilimumab A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab Recruiting
NCT03220009 Phase II Nivolumab + Ipilimumab Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma Withdrawn
NCT03241186 Phase II Nivolumab + Ipilimumab Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma Recruiting
NCT03767348 Phase Ib/II Nivolumab + RP1 RP1 Study of RP1 Monotherapy and RP1 in Combination With Nivolumab Recruiting
NCT03817125 Phase I Nivolumab + SER-401 Vancomycin Nivolumab Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention (MCGRAW) Recruiting
NCT03834623 Phase II CC-122 + Nivolumab Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma Not yet recruiting